OBJECTIVES The authors evaluated the 5-year cumulative incidence of cardiovascular events following Resolute zotarolimus-eluting stent (R-ZES) implantation.
.
Study designs and results have been published previously (13, 14, [16] [17] [18] [19] 21, 22 Yeh et al.
Resolute Pooled Safety Results Adjusted hazard ratios and 95% confidence intervals were calculated for TLF at 5 years stratified by the following baseline covariates: diabetes mellitus, acute coronary syndrome, lesion length, bifurcation, and reference vessel diameter ( Table 4) . patients, showed a lower incidence of very late ST Yeh et al.
Resolute Pooled Safety Results RVD ¼ reference vessel diameter; TLF ¼ target lesion failure.
Resolute Pooled Safety Results indicate that discontinuation of DAPT at 1 year is justified in this patient population, there has been a growing emphasis on individualizing DAPT duration and continuing long-term therapy in those at greater risk for ischemia and lowest risk of bleeding (37, 38) .
Although the patient populations were distinct, the rate of very late ST observed in our analysis of RESOLUTE over years 1 through 5 (0.5%) was comparable to the 0.4% rate of ST observed over 12 to 30 months in the DAPT Study group randomized to Values are mean AE SD, median (interquartile range), % (n/N), or % (n). Tables 2 and 3 .
Abbreviations as in
Yeh et al.
Resolute Pooled Safety Results Additionally, DAPT therapy beyond 1 year was not specified by any of the individual study protocols.
Finally, although we tabulated clinical outcomes across multiple clinical programs, and baseline characteristics in these programs were similar, differences in trial designs exist and direct comparisons should be applied with caution. Resolute Pooled Safety Results
CONCLUSIONS

